Details
| Stereochemistry | RACEMIC |
| Molecular Formula | C9H15NO2.ClH |
| Molecular Weight | 205.682 |
| Optical Activity | ( + / - ) |
| Defined Stereocenters | 0 / 1 |
| E/Z Centers | 0 |
| Charge | 0 |
SHOW SMILES / InChI
SMILES
Cl.CC(=O)OC1CN2CCC1CC2
InChI
InChIKey=LWWSARSTZGNKGV-UHFFFAOYSA-N
InChI=1S/C9H15NO2.ClH/c1-7(11)12-9-6-10-4-2-8(9)3-5-10;/h8-9H,2-6H2,1H3;1H
| Molecular Formula | C9H15NO2 |
| Molecular Weight | 169.2209 |
| Charge | 0 |
| Count |
|
| Stereochemistry | RACEMIC |
| Additional Stereochemistry | No |
| Defined Stereocenters | 0 / 1 |
| E/Z Centers | 0 |
| Optical Activity | ( + / - ) |
| Molecular Formula | ClH |
| Molecular Weight | 36.461 |
| Charge | 0 |
| Count |
|
| Stereochemistry | ACHIRAL |
| Additional Stereochemistry | No |
| Defined Stereocenters | 0 / 0 |
| E/Z Centers | 0 |
| Optical Activity | NONE |
DescriptionCurator's Comment: Description was created using several sources including:
https://www.ncbi.nlm.nih.gov/pubmed/16229863 | https://www.ncbi.nlm.nih.gov/pubmed/12579779 | https://www.ncbi.nlm.nih.gov/pubmed/10845594
Curator's Comment: Description was created using several sources including:
https://www.ncbi.nlm.nih.gov/pubmed/16229863 | https://www.ncbi.nlm.nih.gov/pubmed/12579779 | https://www.ncbi.nlm.nih.gov/pubmed/10845594
Aceclidine is a parasympathomimetic agent used in the treatment of open-angle glaucoma as topical eye drop solution. It is as a muscarinic acetylcholine receptor agonist with weak anticholinesterase activity. Acting directly on the motor end-plate (cholinergic nerve endings) it decreases intraocular pressure and mediates the contraction of iris muscle. Aceclidine increased outflow facility in human eyes in vitro by a direct stimulation of the outflow tissues in the absence of an intact ciliary muscle. This effect was biphasic, occurring at concentrations of 10 uM and lower with no effect at higher concentrations. Passed numerous clinical trials in Russia, France, Italy and other countries and was widely used in Europe but never been in clinical use in USA.
Approval Year
PubMed
| Title | Date | PubMed |
|---|---|---|
| [The selectivity of the action of muscarinic agonists in vivo]. | 1994 Mar-Apr |
|
| Correlation between pK(a) and reactivity of quinuclidine-based catalysts in the Baylis-Hillman reaction: discovery of quinuclidine as optimum catalyst leading to substantial enhancement of scope. | 2003 Feb 7 |
|
| Pharmacological management of night vision disturbances after refractive surgery Results of a randomized clinical trial. | 2005 Sep |
|
| Aceclidine and pilocarpine interact differently with muscarinic receptor in isolated rabbit iris muscle. | 2006 Feb 28 |
|
| [The role of M-cholinoreceptors in the regulation of Th1 and Th2 lymphocyte functions]. | 2008 Mar-Apr |
|
| Aceclidine, brimonidine tartrate, and dapiprazole: comparison of miotic effect and tolerability under different lighting conditions. | 2009 Jan |
|
| Effectiveness of daily use of brimonidine as antimydriatic agent. | 2009 Oct |
|
| Role of cholinergic and cytokine regulation of T cell function in stimulation and inhibition of immune reactions in intoxication by organophosphorus compounds in different doses. | 2009 Sep |
Patents
Sample Use Guides
Instill 2 drops of Glaunorm (2% aceclidine hydrochloride solution) into the conjunctival sac every 8 hours following the doctor's prescription
Route of Administration:
Topical
Human eyes were dissected and perfused. A steady state baseline facility was established for 90 minutes, after which up to four sequential concentrations ranging from 1 nM to 10 mM of aceclidine, were added to the perfusion medium. Outflow facility increased from baseline facility in eyes treated with aceclidine at lower concentrations (1 nM to 1 uM) but remained unchanged at higher concentrations.
| Substance Class |
Chemical
Created
by
admin
on
Edited
Fri Dec 15 15:34:53 GMT 2023
by
admin
on
Fri Dec 15 15:34:53 GMT 2023
|
| Record UNII |
3B22O325Q6
|
| Record Status |
Validated (UNII)
|
| Record Version |
|
-
Download
| Name | Type | Language | ||
|---|---|---|---|---|
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Systematic Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English |
| Classification Tree | Code System | Code | ||
|---|---|---|---|---|
|
NCI_THESAURUS |
C47796
Created by
admin on Fri Dec 15 15:34:53 GMT 2023 , Edited by admin on Fri Dec 15 15:34:53 GMT 2023
|
| Code System | Code | Type | Description | ||
|---|---|---|---|---|---|
|
100000078824
Created by
admin on Fri Dec 15 15:34:53 GMT 2023 , Edited by admin on Fri Dec 15 15:34:53 GMT 2023
|
PRIMARY | |||
|
m9469
Created by
admin on Fri Dec 15 15:34:53 GMT 2023 , Edited by admin on Fri Dec 15 15:34:53 GMT 2023
|
PRIMARY | Merck Index | ||
|
C96880
Created by
admin on Fri Dec 15 15:34:53 GMT 2023 , Edited by admin on Fri Dec 15 15:34:53 GMT 2023
|
PRIMARY | |||
|
228-071-5
Created by
admin on Fri Dec 15 15:34:53 GMT 2023 , Edited by admin on Fri Dec 15 15:34:53 GMT 2023
|
PRIMARY | |||
|
SUB00241MIG
Created by
admin on Fri Dec 15 15:34:53 GMT 2023 , Edited by admin on Fri Dec 15 15:34:53 GMT 2023
|
PRIMARY | |||
|
DTXSID30976587
Created by
admin on Fri Dec 15 15:34:53 GMT 2023 , Edited by admin on Fri Dec 15 15:34:53 GMT 2023
|
PRIMARY | |||
|
6109-70-2
Created by
admin on Fri Dec 15 15:34:53 GMT 2023 , Edited by admin on Fri Dec 15 15:34:53 GMT 2023
|
PRIMARY | |||
|
3B22O325Q6
Created by
admin on Fri Dec 15 15:34:53 GMT 2023 , Edited by admin on Fri Dec 15 15:34:53 GMT 2023
|
PRIMARY | |||
|
170367
Created by
admin on Fri Dec 15 15:34:53 GMT 2023 , Edited by admin on Fri Dec 15 15:34:53 GMT 2023
|
PRIMARY |
| Related Record | Type | Details | ||
|---|---|---|---|---|
|
|
PARENT -> SALT/SOLVATE |
| Related Record | Type | Details | ||
|---|---|---|---|---|
|
|
ACTIVE MOIETY |